Effective August 14, 2023, the following respiratory inhalers have been added to the ADAP formulary: albuterol HFA, beclomethasone dipropionate HFA, budesonide HFA, budesonide/formoterol, fluticasone HFA, fluticasone/salmeterol diskus, fluticasone/vilanterol, ipratropium, montelukast, tiotropium, umeclidinium and vilanterol/umeclidinium/fluticasone furoate.

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic diseases affecting an estimated 20.4 million adults and 12.5 million adults in the U.S., respectively. Asthma is a disease of chronic lung airway inflammation that causes coughing, chest tightness, wheezing or shortness of breath. COPD refers to a group of diseases (including emphysema and chronic bronchitis) that cause airflow blockage and breathing-related problems. The mainstay of treatment for both asthma and COPD is to avoid known triggers that exacerbate symptoms (e.g., smoking) and to use inhaled bronchodilators and anti-inflammatory medications that can improve lung function and prevent exacerbations.

Although neither asthma nor COPD can be cured, these adverse outcomes can be reduced and prevented with optimal respiratory inhaler treatment. The addition of respiratory inhalers to the ADAP formulary will reduce mortality and improve the quality of life of people with HIV in California who also have asthma or COPD.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of respiratory inhalers.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov ).

Thank you,